Trilogy Laboratories Acquires YNS Cosmeceuticals

Trilogy Laboratories, led by pharmaceutical scientist Dr. Kristen Flaharty, identified YNS as a target due to its alignment with clinical formulation standards. By absorbing the brand, Trilogy intends to leverage its FDA-registered manufacturing infrastructure to support future growth. The transition is designed to provide continuity for existing customers, ensuring that current product formulations remain unchanged while the company begins to integrate enhanced research capabilities.

Dr. Kristen Flaharty, who oversees the firm’s development, and Dr. Patrick Flaharty, a dual fellowship-trained facial cosmetic surgeon, will spearhead the integration. Their combined focus centers on applying rigorous ingredient science and delivery system optimization to the brand’s future innovations. While Trilogy plans to invest in an expanded digital experience and educational resources, the company maintains that any forthcoming additions to the YNS catalog will prioritize straightforward, effective skincare rather than the industry trend of increasingly complex regimens.